Back to companies

Ionis Pharmaceuticals Inc: Premium Databases

Ionis Pharmaceuticals Inc Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Ionis Pharmaceuticals Inc Insights data

Headline Published Journalists
Showing 3 of 50+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 21 Apr 2021 Lorem
LoA Update: Ionis Pharmaceuticals' donidalorsen sodium for HAE sees an 8-point spike in FDA regulatory potential following positive Phase II 07 Apr 2021 William Newton
Ionis’ prekallikrein target for Phase IIa IONIS-PKK-LRx stands on par with approved prophylactic drugs in HAE; early data draws expert enthusiasm on activity 16 Mar 2021 William Newton
Akcea/Ionis’ AKCEA-APOCIII-LRx has bright efficacy prospects in Phase II hypertriglyceridemia trial but value in impacting CVD risk still debatable, experts say 25 Sep 2019 Reynald Castaneda


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer